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Abstract: Since the arrival of the global COVID-19 pandemic scientists around the world have been
working to understand the pathological mechanisms resulting from infection. There has gradually
been an understanding that COVID-19 triggers a widespread endotheliopathy and that this can result
in a widespread thrombosis and in particular a microthrombosis. The mechanisms involved in the
microthrombosis are not confined to infection and there is evidence that patients with aneurysmal
sub-arachnoid haemorrhage (SAH) also suffer from an endotheliopathy and microthrombosis. In this
article we attempt to shed light on similarities in the underlying processes involved in both diseases
and suggest potential treatment options.
Keywords: COVID-19; microthrombosis; delayed cerebral ischemia; subarachnoid haemorrhage
1. Introduction
Since the beginning of 2020, COVID-19 has spread rampantly globally, with over 50
million confirmed cases and deaths exceeding one million. In unison with monumental
efforts to manage the clinical caseload, there has been a worldwide effort to understand
the virus and its effects on the body, and to develop appropriate management strategies.
Additionally, respiratory failure coagulopathies are a devastating central mechanism of
COVID-19. Interventional neuroradiology has been on the frontline with this disease in
clinical care and in managing patients presenting with acute large vessel occlusions. Osten-
sibly, the interventional neuroradiologist and their knowledge base may not extend much
beyond this clinical role. However, diseases with which we are familiar—subarachnoid
hemorrhage and delayed cerebral ischemia (DCI)—appear to have more in common with
COVID-19 than previously appreciated.
This article attempts to highlight several commonalities between DCI and COVID-19,
namely, endotheliopathy, derangement in the von Willebrand Factor (vWF)-platelet axis,
and microthrombosis. We also suggest a potential mechanism for the rare occurrences
of thrombosis seen after vaccination. We suggest potential therapies that may serve as
treatment strategies for both diseases.
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2. Overview of the vWF, ADAMTS13, Platelets, and Thromboinflammation
To understand the potential similarities between DCI and COVID-19, it is essential
first to understand the critical role of vWF in normal hemostasis. Von Willebrand Factor is
produced exclusively by endothelial cells (ECs) and megakaryocytes. During its biosyn-
thesis, vWF undergoes significant dimerization and multimerization during production
and post-translational processing. It is stored within the Weibel–Palade bodies (WPB) of
the endothelial cells or megakaryocytes’ alpha granules (Figure 1). Although restricted
to ECs, there are differences in the synthesis of vWF within the body’s different vascular
beds, with the small vessels of the lung and brain expressing higher levels of vWF than
similar-sized vessels of the liver or kidney [1]. The stored vWF multimers are enriched
into Ultra-Large vWF (ULvWF) and prothrombotic forms released upon stimulation of the
endothelial cells (Figure 2) and platelets. Von Willebrand Factor is secreted into the plasma
in this ultra-large form that consists of several hundred vWF monomers. The biological
function of vWF depends mainly on the size of its multimers [2–5]. The larger multimers
are more likely to bind platelets and promote platelet adhesion in circulating blood; thus,
ULvWF multimers are the most biologically active, inducing platelet aggregation [6]. Given
the highly pro-thrombotic potential of ULvWF, mechanisms exist to degrade the ULvWF
into smaller vWF forms, which are active in hemostasis but are no longer prothrombotic,
to maintain a delicate hemostatic balance. This is achieved via the vWF-cleaving protease
ADAMTS13 (A Disintegrin-like and Metalloprotease with Thrombospondin type 1-motif
13). The ADAMTS13 enzyme targets the A2 domain of the vWF and cleaves the hyper-
active ULvWF multimers into smaller and less biologically active forms (Figure 3). Two
contrasting disorders exemplify disturbances in this pathway—thrombotic thrombocy-
topenic purpura, where either an inherited deficiency of ADAMTS13 or the development of
autoantibodies to ADAMTS13 results in a small vessel and arterial thrombotic phenotype,
or type 2 von Willebrand’s Disease, in which large vWF multimers are defective or absent,
resulting in a lifelong bleeding disorder.
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The endothelial glycocalyx is a complex layer of proteins and carbohydrates that
covers the vascular endothelium, both arterial and venous, which is composed principally
of plasma proteins, proteoglycans, and glycoproteins along with their bound glycosamino-
glycan (GAG) chains. Core proteoglycans, such as the syndecans and glypicans, support
binding sites for GAGs that include heparan sulfate and chondroitin sulfate, which in
turn protrude into the vascular lumen. The glycocalyx has many physiological functions
that include the vascular anticoagulation and mechano-transduction of shear stress. The
net negative charge of the glycocalyx, generated by the anionic oligosaccharides from
which it is composed, results in an electrostatic repulsion against platelets and red blood
cells, whilst the depth of the glycocalyx helps to physically separate blood cells from the
endothelial surface. To date, there is limited literature available on the interaction between
vWF and the glycocalyx; however, some studies suggest that the glycocalyx plays a role in
tethering secreted and circulating vWF to the endothelium [7,8].
Von Willebrand Factor has three well-recognized hemostatic functions, which me-
diate platelet–platelet interactions, platelet–collagen interactions, and act as a carrier for
Factor VIII. Research also suggests that it plays a role in inflammation, angiogenesis, and
smooth muscle cell proliferation. Upon secretion from the ECs, the ULvWF is in its glob-
ular form (Figure 2), with a proportion of the ULvWF released remaining bound to the
endothelium [9,10]. Under hemodynamic shear stress, ULvWF unfolds, and binding sites
for platelets (Figure 4), self-association, and adhesion to the vessel wall are exposed. Previ-
ous studies have shown that ULvWF molecules can self-associate into long “strings” in the
direction of flow, both arterial and venous, that bind to platelets and leukocytes and adhere
to the endothelium [10–12]. These strings can be remarkably long and have been seen to
reach up to 1 mm in length [10]. The ULvWF multimers released from the WPBs have
lower shear stress for unfolding. They, therefore, may represent the initiating molecules for
this self-assembly process, which leads to hyper-adhesive strings capturing platelets.
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 4 of 13 
 
 
in turn protrude into the vascular lumen. The glycocalyx has many physiological func-
tions that include the vascular anticoagulation and mechano-transduction of shear stress. 
The net negative charge of the glycocalyx, generated by the anionic oligosaccharides from 
which it is composed, results in an electrostatic repulsion against platelets and red blood 
cells, whilst the depth of the glycocalyx helps to physically separate blood cells from the 
endothelial surface. To date, there is limited literature available on the interaction between 
vWF and the glycocalyx; however, so e studies suggest that the glycocalyx plays a role 
in tethering secreted and circulating vWF to the endothelium [7,8]. 
Von Will brand Factor has three well-r cognized he ostatic functions, which medi-
ate platelet–p atelet interactions, platelet–collagen int ractions, and act as a carrier for Fac-
tor VIII. Research also suggests that it plays a role in inflammatio , ngiogenesis, and 
smo th muscle cell proliferation. Upon secretion from the ECs, the ULvWF is i  its glob-
ular for  (Figure 2), with a proporti  of the ULvWF released remaining bou d to the 
endothelium [9,10]. Under hem dynamic shear stress, ULvWF unfolds, a d inding sites 
for plat ets (Figure 4), s lf-association, and adhesion to the vessel wall re exposed. Pr -
vious studies have shown that ULvWF molecul  can self-associate into long “ trings” in 
the direction of flow, bo  arterial and v nou , that bind t  platelets a d leukocytes and 
adhere to the endothelium [10–12]. These strings can be r markably long and have been 
seen to reach up to 1 mm in length [10]. The ULvWF multimers released from the WPBs 
have lower shear stress for unfolding. They, therefore, may represent the initiating mole-
cules for this self-assembly process, which leads to hyper-adhesive strings capturing 
platelets.  
 
Figure 4. Unfurling of the vWF also exposes the A1 domain that represents the binding site for platelets to vWF via the 
platelet GPIb receptor. 
The binding of platelets to the ULvWF occurs via the GPIb receptor at the A1 domain 
(Figure 4). This receptor is usually not exposed when the ULvWF is in its globular form 
and cannot bind to platelets. Once ULvWF unfurls, secondary to shear stress, the receptor 
is exposed and binds very strongly to platelets. Platelets bound to the ULvWF are acti-
vated with conformational changes to the GPIIbIIIa receptor on their surface, allowing 
platelet–platelet binding (Figure 5) and the further formation of a platelet plug (Figures 6 
platelet PIb receptor.
J. Clin. Med. 2021, 10, 2646 5 of 13
is exposed and binds very strongly to platelets. Platelets bound to the ULvWF are activated
with conformational changes to the GPIIbIIIa receptor on their surface, allowing platelet–
platelet binding (Figure 5) and the further formation of a platelet plug (Figures 6 and 7).
In addition to the A1 domain becoming exposed, exposure of the A2 domain during the
unfurling of ULvWF allows the cleavage of ULvWF into the smaller, less biologically active
molecules, as mentioned earlier. These two mechanisms need to work in balance to prevent
prothrombotic or prohemorrhagic conditions, as mentioned earlier. Both platelet-decorated
and platelet-free vWF strings are cleaved by ADAMTS13 at similar rates, suggesting that
platelet binding has little influence on proteolysis [12]. If left unchecked, the release of
ULvWF can result in microthrombosis.
Given that vWF and ULvWF are produced and released by endothelial cells, levels
of vWF have been used as an indicator of an underlying endothelial injury, termed en-
dotheliopathy. Therefore, the plasma level of vWF can be used as a marker of endothelial
activation, vascular inflammation, and endotheliopathy. Raised levels of vWF are associ-
ated with acute respiratory distress syndrome and sepsis, and correlate independently to
mortality [13,14], with evidence that the vWF axis is involved in delayed cerebral ischemia
(DCI) secondary to aneurysmal subarachnoid hemorrhage (SAH) as well as COVID-19.
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were seen in the brains of patients who had died of aneurysmal SAH [15–18]. Stein et al.
performed a histological analysis of the brains of 29 patients who had died from aneurysmal
SAH [19]. The authors found a strong correlation between the extent of microvascular
thrombi and the presence of ischemic infarctions. Microvascular thrombosis was most
prevalent in brain areas with maximal neuronal necrosis, and they observed a bimodal
peak in the development of microthrombosis formation with one peak in the first three
days and a second peak between days 7 and 15. The results of this study suggest that
microthrombosis plays a vital role in the development of DCI.
A large number of animal studies have shown microthrombosis developing secondary
to induced SAH. In rodent models of SAH using autologous blood infusion, microthrom-
bosis and occluded blood vessels occurred throughout the brain within two days post-
SAH [20] and could be observed for up to seven days post-ictus [21]. Microthrombosis has
also been observed in puncture models of SAH [22–24]; however, as the puncture itself
could act as a source for microthrombi, the autologous blood transfusion models may
provide greater insight into the role of microthrombosis.
Von Willebrand Factor and ADAMTS13 have also been coplayers in microthrombosis.
Muroi et al. investigated the role of ADAMTS13 in SAH in a mouse model [25]. They
showed that the systemic administration of ADAMTS13 achieved significant ameliora-
tion of microthrombosis and neurologic performance with a reduction in the amount of
apoptotic and degenerative neurons. Remarkably, ADAMTS13 had no significant effect
on vasospasm, and the administration of ADAMTS13 neither increased the amount of
subarachnoid blood nor prolonged the bleeding time.
Vergouwen et al. used a prechiasmatic injection model of SAH to assess the po-
tential therapeutic benefit of ADAMTS13 treatment on SAH-induced microthrombosis
formation [26]. They used recombinant human ADAMTS13 (rADAMTS13) delivered in-
travenously to wild-type and ADAMTS13 knockout mice following SAH induction. They
showed a trend towards a reduction in microthrombosis in wild-type mice and a significant
reduction in microthrombosis in the knockout mice.
Wan et al. sought to determine the role of vWF and ADAMTS13 in SAH [27]. They
used a prechiasmatic blood injection model in wild-type controls, ADAMTS13 knockout,
and vWF knockout, and wild-type mice were given recombinant rADAMTS13. They
showed that the vWF knockout mice and those treated with rADAMTS13 had significantly
less neuronal injury than the wild-type controls (64 vs. 185 neurons, p < 0.01; 45 vs. 185
neurons, p < 0.001, respectively). There was also a trend towards reduced neuronal injury
in the ADAMTS13 knockout mice. The authors suggest that this study demonstrates the
critical role vWF plays in early brain injury after SAH. This study was not designed to
observe the development of microthrombosis, which typically occurs at 48 h post-ictus in
mice; however, taken together with previous studies, it suggests that the vWF-ADAMTS13
axis is involved in DCI.
In a pilot study of 40 consecutive patients, Kumar et al. assessed the ADAMTS13 and
vWF levels on days 0, 1, 3, 5, 7, and 10 postictus compared to healthy controls [28]. They
showed that vWF activity and vWF antigen (the routine marker for vWF) were significantly
higher in SAH patients compared to controls at each time-point (p < 0.0001). Similarly, there
was a marked reduction in plasma ADAMTS13 activity in the SAH patients compared to
controls (p < 0.0001), as was the ratio of plasma ADAMTS13 and vWF antigen (p < 0.0001).
Similar results were shown previously by Vergouwen et al., with more marked de-
creases in ADAMTS13 seen in patients who developed DCI than in those that did not
(p = 0.0001) [29]. They also observed more pronounced increases in vWF antigen and the
vWF-precursor, vWF propeptide (p = 0.02 and 0.004, respectively).
Further studies have shown a derangement in the glycocalyx lining of the endothelium
in patients with SAH [30], consistent with other groups’ findings suggesting a significant
insult to the vascular endothelium post-SAH. Collectively, these observations indicate that
the vWF–ADAMTS13 axis plays an essential role in DCI development.
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4. Evidence of Abnormalities in COVID-19
There is an increasing recognition that COVID-19 causes endotheliopathy [31–36],
and widespread microthrombosis is seen using contrast-enhanced ultrasound [37,38].
Autopsy studies have shown evidence of extensive, potentially fatal endotheliopathy.
Varga et al. demonstrated a widespread endotheliopathy affecting the pulmonary, renal,
gastrointestinal, and hepatic vessels on post mortem examinations of three patients with
COVID-19 [35]. In one of the cases, the authors reported that “most of the small vessels
appeared congested”. In another case, the patient died from bowel ischemia with evidence
of underlying endotheliopathy.
In a case series of COVID-19 pulmonary autopsies, it was revealed that, alongside
diffuse alveolar damage, numerous localized platelet-rich microthrombi and foci of hemor-
rhage were present in the lungs [39]. The authors posited pulmonary-localized thrombotic
microangiopathy as a key to the pathogenesis of COVID-19, with others also suggesting
microthrombosis as a critical driver in the disease process [40]. In the case series of Carsena
et al., microthrombi in vessels <1 mm in diameter were seen in 87% of cases [41].
Multiple studies also revealed microthrombosis on brain biopsy and post mortem
studies [42–45]. Consistent with the fact that COVID-19 causes a widespread endotheliopa-
thy is the evidence of marked rises in vWF. The earliest report of a substantial elevation
of vWF was that by Escher et al., who reported an increase in vWF of over 500% [34].
Subsequently, Goshua et al. reported marked elevations in plasma vWF concentrations
in COVID-19 patients with increased levels associated with disease severity. Mean vWF
antigen levels of those admitted to the ICU were 565 ± 199% vs. 278 ± 133% of non-ICU
patients (p < 0.0001). Other groups have also shown marked elevations of vWF in patients
with COVID-19 [46–48]. Rauch et al. looked at the clinical course of patients with COVID-
19 in relationship to their vWF levels on admission [49]. They showed that patients with
the initial highest vWF levels required more oxygen support.
In contrast, the small cohort (n = 10) attended the emergency department present-
ing normal vWF levels and required neither hospitalization nor supplementary oxygen.
Ladikou et al. also observed increased vWF antigen levels in ICU COVID-19 patients,
positively correlating with the patients’ ages [36]. This group also showed reduced levels
of ADAMTS13 (49.7%), and it was estimated that this reduction in plasma ADAMTS13
levels was secondary to the excess release of vWF and consumption. South et al. measured
a six-fold increase in UL-vWF levels of COVID-19 patients compared to healthy controls,
possibly due to an imbalance in IL-6-driven release and reduced ADAMTS13 [50]. More
recently, Philippe et al. [51] showed a strong association between ULvWF and outcome.
In the most extensive study to date (n = 208), the authors showed a marked difference
in the vWF:Ag levels between critical (507%) and noncritical (288%) patients, which was
highly significant (p < 0.0001). On further analysis, the authors showed that the ROC for
vWF:Ag was the most predictive for mortality with an AUC of 0.92 (95% CI 0.88–0.96) and
a cut-off level of vWF:Ag (423%), able to predict mortality in univariate and multivariate
modeling, the Kaplan–Meier estimator, and the Cox proportional hazard. Taken together,
these studies suggest that there is a marked abnormality in the ratio of ULvWF and the
regulatory enzyme ADAMTS13 that tips the system into a markedly prothrombotic state.
Huisman et al. [52] were the first to show a mean vWF:ADAMTS13 ratio of 8.5 (normal
0.5–2) from 12 patients admitted to the ICU. Subsequently, Mancini et al. [53] demonstrated
similar findings with an elevated vWF:Ag to the ADAMTS13 activity ratio, which was
strongly associated with disease severity with the worst ratio, 8.3, seen in the patients that
required high-intensity care (intubation and mechanical ventilation) compared to those
requiring low-intensity care, 3.42 (p < 0.001). Another disease caused by an abnormal
vWF:ADAMTS13 ratio is thrombotic thrombocytopenic purpura (TTP). In the acquired
form of TTP, a circulating autoantibody that inhibits the function of ADAMTS13 is pro-
duced; hence, vWF platelet microthrombi formation can occur unhindered due to a lack
of functioning ADAMTS13. In a sense, acquired TTP is caused by an abnormal ratio
of vWF, which may be released in normal quantities, and nonfunctioning ADAMTS13,
J. Clin. Med. 2021, 10, 2646 9 of 13
whereas in COVID-19, there is a massive release of ULvWF and regular or reduced levels
of ADAMTS13, secondary to consumption, that result in microthrombosis. Doevelaar
et al. [54] recently published the results of their series of 75 patients in whom a vWF multi-
mer gel analysis was performed. The other groups mentioned above showed an increase
in the vWF:Ag levels and a derangement in the vWF:ADAMTS13 ratio. They also showed
that a vWF multimer pattern that resembled TTP with a smeary triplet pattern, an indicator
of ADAMTS13 dysfunction, was seen in 39% of cases. The authors state “COVID-19 is
associated with a substantial increase in von Willebrand factor levels, which can exceed the
ADAMTS13 processing capacity resulting in the formation of large von Willebrand factor
multimers indistinguishable from thrombotic thrombocytopenic purpura”.
A summary of the core similarities seen between COVID-19 and SAH is shown in
Table 1.
Table 1. Summary of the existing data analysing the vWF-ADAMTS13 axis in both conditions.
COVID-19 SAH
Raised vWF levels Y Y
Raised ULvWF levels Y Not investigated
Abnormal ADAMTS13 level Y Y
Evidence of microthrombosis Y Y
5. Potential Treatment Strategies
Overall, there is growing evidence for underlying endotheliopathies in both DCI and
COVID-19, expressed by consistent rises in vWF. The significant increases in vWF could
result in a consumptive effect on the available ADAMTS13 levels and cause a prothrombotic
state. This implies potential benefits of early interventions targeting the vWF-ADAMTS13
axis in both diseases.
5.1. GPIb Receptor Antagonists
As mentioned earlier, platelets bind to the GPIb receptor, located on the A1 domain,
on ULvWF. Two available drugs are inhibiting this interaction—caplacizumab (Sanofi) and
anfibatide (Lees Pharma). Caplacizumab targets the A1 domain of the ULvWF, inhibiting
the interaction between ULvWF and platelets, hence preventing platelet adhesion and
microvascular thrombosis. Two trials investigated caplacizumab to treat thrombotic throm-
bocytopenic purpura (TTP): TITAN and HERCULES [55,56]. Both trials met their primary
end-points along with good safety profiles (reduced numbers of thromboembolic adverse
events). In total, 11.4% of caplacizumab-treated patients and 43.2% of placebo-treated
patients experienced one or more major thromboembolic events, an exacerbation, or died
in the TITAN study. Bleeding events were generally mild or moderate, with epistaxis
and gingival bleeding in TITAN. Not surprisingly, bleeding risk was higher in the capla-
cizumab group (54% of patients vs. 38% in the placebo arm). Of the 101 bleeding-related
adverse events, 83% (n = 84) were mild (transient and not requiring more than minimal
intervention), and 14% were moderate (alleviated by therapeutic intervention and causing
discomfort, but without significant or permanent risk of harm). In the HERCULES cohort,
caplacizumab 10 mg significantly reduced the time-to-confirmed normalization of the
platelet count by 39% compared with placebo (median 2.97 vs. 4.79 days; p = 0.005), with
complete remission observed more frequently in the caplacizumab arm (81% vs. 46%).
Anfibatide, a snake-venom-derived GPIb inhibitor, is an alternative agent and is
currently undergoing investigation for TTP use. For caplacizumab, and in all likelihood
anfibatide too, plasma-derived von Willebrand factor concentrate can act as an antidote.
Both of these agents would represent potential treatment options for patients with SAH;
however, given that they inhibit binding platelets to vWF and platelet activation, their use
should be considered after the ruptured aneurysm is secured. Inhibiting the initial stage of
platelet–vWF binding would be advantageous since ULvWF platelet strings are sufficient
to occlude the microvasculature alone without the need for platelet–platelet binding.
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Several authors have now suggested that the use of caplacizumab or anfibatide [51,54,57]
may represent a potential treatment option for patients with COVID-19. We believe that
the use of GP1b receptor antagonists would be feasible and should be considered for
patients with vWF:Ag levels of over 200% and vWF:ADAMTS13 ratios of ≥4 based on the
existing literature.
5.2. N-Acetyl Cysteine
Intravenous N-Acetyl Cysteine (NAC), which has been shown to reduce the size of
vWF multimers, represents another attractive treatment option and has a long history
and familiarity amongst clinicians. In patients with elevated vWF levels, but normal
ADAMTS13 levels, IV NAC could aid in the degradation of ULvWF; in patients with more
markedly deranged vWF:Ag and ADAMTS13 levels, it could be used in conjunction with
GPIIbIIIa blockers, as this combination has previously been shown to significantly impair
clot formation [58]. When using these drugs, it is essential to note that high vWF levels
may impede the effect of GPIIbIIIa antagonists, and eptifibatide may offer advantages over
tirofiban in this regard [59]. It is important to note that NAC should be used as part of a
preventative strategy and, therefore, would need to be started early in patients at high risk
of disease progression, since NAC will not degrade any microthrombi already formed. This
strategy could also be readily applied to patients with SAH with IV NAC instigated on
admission and the instigation of GPIIbIIIa receptor blockade used in select cases following
the aneurysm’s securing. Similarly, the fact that it is the GPIIbIIIa receptor that is activated
by the binding of platelets to the GPIb receptor could explain why aspirin fails to result
in the improvement of patients with SAH [60], but dual antiplatelet therapy has shown
promise [61].
5.3. Recombinant ADAMTS13
Alternatively, recombinant ADAMTS13 could be given to patients to assist in the
degradation of ULvWF. Recombinant ADAMTS13 would allow a normalization of the
abnormal vWF:ADAMTS13 ratio in patients with COVID-19. The use of rADAMTS13
could be used adjunctively with other therapies, with a potential combined approach
of rADAMTS13 given alongside GPIb antagonists, GPIIbIIIa antagonists, or IV NAC.
In patients with ruptured aneurysms, rADAMTS13 could be started before definitive
aneurysm protection surgery with additional antiplatelet treatments delivered afterward.
5.4. Plasma Exchange
Plasma exchange represents a further treatment option that we believe is more suit-
able for patients with COVID-19. Furthermore, rather than the original theory of using
convalescent plasma to provide antibodies against the virus, plasma may, in fact, work by
providing replacement ADAMTS13. As with other treatment options, early detection of
patients with the most deranged vWF:ADAMTS13 ratio is essential in determining who
would benefit the most from this treatment.
6. Conclusions
There is evidence that both COVID-19 and SAH result in endotheliopathy and the
release of ULvWF, microthrombosis, and ischemia. Targeting this pathway with drugs
such as GPIb antagonists and intravenous NAC or restoring the hemostatic balance using
infusions of rADAMTS13 represent promising targets for both diseases.
Author Contributions: Conceptualization and development of theory, P.B.; writing—original draft
preparation, P.B.; writing—review and editing, P.B., L.M., A.E.H., D.F., T.A., M.A., and H.B.;
manuscript preparation and editing, O.J.; guarantor, H.H. All authors have read and agreed to
the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors have no conflict of interest.
J. Clin. Med. 2021, 10, 2646 11 of 13
References
1. Yamamoto, K.; de Waard, V.; Fearns, C.; Loskutoff, D.J. Tissue Distribution and Regulation of Murine von Willebrand Factor Gene
Expression in Vivo. Blood 1998, 92, 2791–2801. [CrossRef] [PubMed]
2. Crawley, J.T.B.; de Groot, R.; Xiang, Y.; Luken, B.M.; Lane, D.A. Unraveling the Scissile Bond: How ADAMTS13 Recognizes and
Cleaves von Willebrand Factor. Blood 2011, 118, 3212–3221. [CrossRef]
3. Moake, J.L.; Chow, T.W. Increased von Willebrand Factor (VWf) Binding to Platelets Associated with Impaired VWf Breakdown
in Thrombotic Thrombocytopenic Purpura. J. Clin. Apher. 1998, 13, 126–132. [CrossRef]
4. Kumar, R.A.; Moake, J.L.; Nolasco, L.; Bergeron, A.L.; Sun, C.; Dong, J.; McIntire, L.V. Enhanced Platelet Adhesion and
Aggregation by Endothelial Cell-Derived Unusually Large Multimers of von Willebrand Factor. Biorheology 2006, 43, 681–691.
5. Sporn, L.A.; Marder, V.J.; Wagner, D.D. Inducible Secretion of Large, Biologically Potent von Willebrand Factor Multimers. Cell
1986, 46, 185–190. [CrossRef]
6. Arya, M.; Anvari, B.; Romo, G.M.; Cruz, M.A.; Dong, J.-F.; McIntire, L.V.; Moake, J.L.; López, J.A. Ultralarge Multimers of von
Willebrand Factor Form Spontaneous High-Strength Bonds with the Platelet Glycoprotein Ib-IX Complex: Studies Using Optical
Tweezers. Blood 2002, 99, 3971–3977. [CrossRef]
7. De Ceunynck, K.; De Meyer, S.F.; Vanhoorelbeke, K. Unwinding the von Willebrand Factor Strings Puzzle. Blood 2013, 121,
270–277. [CrossRef]
8. Choi, S.J.; Lillicrap, D. A Sticky Proposition: The Endothelial Glycocalyx and von Willebrand Factor. J. Thromb. Haemost. JTH
2020, 18, 781–785. [CrossRef]
9. André, P.; Denis, C.V.; Ware, J.; Saffaripour, S.; Hynes, R.O.; Ruggeri, Z.M.; Wagner, D.D. Platelets Adhere to and Translocate on
von Willebrand Factor Presented by Endothelium in Stimulated Veins. Blood 2000, 96, 3322–3328. [CrossRef] [PubMed]
10. Dong, J.; Moake, J.L.; Nolasco, L.; Bernardo, A.; Arceneaux, W.; Shrimpton, C.N.; Schade, A.J.; McIntire, L.V.; Fujikawa, K.; López,
J.A. ADAMTS-13 Rapidly Cleaves Newly Secreted Ultralarge von Willebrand Factor Multimers on the Endothelial Surface under
Flowing Conditions. Blood 2002, 100, 4033–4039. [CrossRef] [PubMed]
11. Padilla, A.; Moake, J.L.; Bernardo, A.; Ball, C.; Wang, Y.; Arya, M.; Nolasco, L.; Turner, N.; Berndt, M.C.; Anvari, B.; et al. P-Selectin
Anchors Newly Released Ultralarge von Willebrand Factor Multimers to the Endothelial Cell Surface. Blood 2004, 103, 2150–2156.
[CrossRef]
12. Huang, J.; Roth, R.; Heuser, J.E.; Sadler, J.E. Integrin Alpha(v)Beta(3) on Human Endothelial Cells Binds von Willebrand Factor
Strings under Fluid Shear Stress. Blood 2009, 113, 1589–1597. [CrossRef] [PubMed]
13. Ware, L.B.; Conner, E.R.; Matthay, M.A. Von Willebrand Factor Antigen Is an Independent Marker of Poor Outcome in Patients
with Early Acute Lung Injury. Crit. Care Med. 2001, 29, 2325–2331. [CrossRef] [PubMed]
14. Ware, L.B.; Eisner, M.D.; Thompson, B.T.; Parsons, P.E.; Matthay, M.A. Significance of von Willebrand Factor in Septic and
Nonseptic Patients with Acute Lung Injury. Am. J. Respir. Crit. Care Med. 2004, 170, 766–772. [CrossRef]
15. Hasegawa, T.; Watanabe, H.; Ishii, S. Studies of Intravascular Components in Cerebral Vasospasm Following Subarachnoid
Hemorrhage. Neurosurg. Rev. 1980, 3, 93–100. [CrossRef] [PubMed]
16. Hasegawa, T. Studies of intravascular components with cerebral vasospasm following subarachnoid hemorrhages with particular
regard to platelet and blood coagulation functions (author’s transl). Neurol. Med. Chir. 1980, 20, 473–480. [CrossRef]
17. Suzuki, S.; Suzuki, M.; Iwabuchi, T.; Kamata, Y. Role of Multiple Cerebral Microthrombosis in Symptomatic Cerebral Vasospasm:
With a Case Report. Neurosurgery 1983, 13, 199–203. [CrossRef]
18. Suzuki, S.; Kimura, M.; Souma, M.; Ohkima, H.; Shimizu, T.; Iwabuchi, T. Cerebral Microthrombosis in Symptomatic Cerebral
Vasospasm—A Quantitative Histological Study in Autopsy Cases. Neurol. Med. Chir. 1990, 30, 309–316. [CrossRef]
19. Stein, S.C.; Browne, K.D.; Chen, X.-H.; Smith, D.H.; Graham, D.I. Thromboembolism and Delayed Cerebral Ischemia after
Subarachnoid Hemorrhage: An Autopsy Study. Neurosurgery 2006, 59, 781–787. [CrossRef] [PubMed]
20. Sabri, M.; Ai, J.; Lakovic, K.; D’abbondanza, J.; Ilodigwe, D.; Macdonald, R.L. Mechanisms of Microthrombi Formation after
Experimental Subarachnoid Hemorrhage. Neuroscience 2012, 224, 26–37. [CrossRef] [PubMed]
21. Wang, Z.; Chen, G.; Zhu, W.-W.; Bian, J.-Y.; Shen, X.-O.; Zhou, D. Influence of Simvastatin on Microthrombosis in the Brain after
Subarachnoid Hemorrhage in Rats: A Preliminary Study. Ann. Clin. Lab. Sci. 2010, 40, 32–42.
22. Sehba, F.A.; Bederson, J.B. Mechanisms of Acute Brain Injury after Subarachnoid Hemorrhage. Neurol. Res. 2006, 28, 381–398.
[CrossRef] [PubMed]
23. Sehba, F.A.; Mostafa, G.; Friedrich, V.; Bederson, J.B. Acute Microvascular Platelet Aggregation after Subarachnoid Hemorrhage.
J. Neurosurg. 2005, 102, 1094–1100. [CrossRef]
24. Friedrich, V.; Flores, R.; Muller, A.; Sehba, F.A. Luminal Platelet Aggregates in Functional Deficits in Parenchymal Vessels after
Subarachnoid Hemorrhage. Brain Res. 2010, 1354, 179–187. [CrossRef] [PubMed]
25. Muroi, C.; Fujioka, M.; Mishima, K.; Irie, K.; Fujimura, Y.; Nakano, T.; Fandino, J.; Keller, E.; Iwasaki, K.; Fujiwara, M. Effect of
ADAMTS-13 on Cerebrovascular Microthrombosis and Neuronal Injury after Experimental Subarachnoid Hemorrhage. J. Thromb.
Haemost. JTH 2014, 12, 505–514. [CrossRef] [PubMed]
26. Vergouwen, M.D.I.; Knaup, V.L.; Roelofs, J.J.T.H.; de Boer, O.J.; Meijers, J.C.M. Effect of Recombinant ADAMTS-13 on Mi-
crothrombosis and Brain Injury after Experimental Subarachnoid Hemorrhage. J. Thromb. Haemost. JTH 2014, 12, 943–947.
[CrossRef]
J. Clin. Med. 2021, 10, 2646 12 of 13
27. Wan, H.; Wang, Y.; Ai, J.; Brathwaite, S.; Ni, H.; Macdonald, R.L.; Hol, E.M.; Meijers, J.C.M.; Vergouwen, M.D.I. Role of von
Willebrand Factor and ADAMTS-13 in Early Brain Injury after Experimental Subarachnoid Hemorrhage. J. Thromb. Haemost. JTH
2018, 16, 1413–1422. [CrossRef]
28. Kumar, M.; Cao, W.; McDaniel, J.K.; Pham, H.P.; Raju, D.; Nawalinski, K.; Frangos, S.; Kung, D.; Zager, E.; Kasner, S.E.; et al.
Plasma ADAMTS13 Activity and von Willebrand Factor Antigen and Activity in Patients with Subarachnoid Haemorrhage.
Thromb. Haemost. 2017, 117, 691–699. [CrossRef]
29. Vergouwen, M.D.I.; Bakhtiari, K.; van Geloven, N.; Vermeulen, M.; Roos, Y.B.W.E.M.; Meijers, J.C.M. Reduced ADAMTS13
Activity in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage. J. Cereb. Blood Flow Metab. Off. J. Int. Soc.
Cereb. Blood Flow Metab. 2009, 29, 1734–1741. [CrossRef]
30. Bell, J.D.; Rhind, S.G.; Di Battista, A.P.; Macdonald, R.L.; Baker, A.J. Biomarkers of Glycocalyx Injury Are Associated with Delayed
Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage: A Case Series Supporting a New Hypothesis. Neurocrit.
Care 2017, 26, 339–347. [CrossRef]
31. Jung, F.; Krüger-Genge, A.; Franke, R.P.; Hufert, F.; Küpper, J.-H. COVID-19 and the Endothelium. Clin. Hemorheol. Microcirc.
2020, 75, 7–11. [CrossRef]
32. Goshua, G.; Pine, A.B.; Meizlish, M.L.; Chang, C.-H.; Zhang, H.; Bahel, P.; Baluha, A.; Bar, N.; Bona, R.D.; Burns, A.J.; et al.
Endotheliopathy in COVID-19-Associated Coagulopathy: Evidence from a Single-Centre, Cross-Sectional Study. Lancet Haematol.
2020. [CrossRef]
33. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.;
et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020. [CrossRef]
34. Escher, R.; Breakey, N.; Lämmle, B. Severe COVID-19 Infection Associated with Endothelial Activation. Thromb. Res. 2020, 190, 62.
[CrossRef]
35. Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka,
F.; Moch, H. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet 2020. [CrossRef]
36. Ladikou, E.E.; Sivaloganathan, H.; Milne, K.M.; Arter, W.E.; Ramasamy, R.; Saad, R.; Stoneham, S.M.; Philips, B.; Eziefula, A.C.;
Chevassut, T. Von Willebrand Factor (VWF): Marker of Endothelial Damage and Thrombotic Risk in COVID-19? Clin. Med. 2020.
[CrossRef] [PubMed]
37. Tee, A.; Wong, A.; Yusuff, T.; Rao, D.; Sidhu, P. Contrast-Enhanced Ultrasound (CEUS) of the Lung Reveals Multiple Areas of
Microthrombi in a COVID-19 Patient. Intensive Care Med. 2020. [CrossRef]
38. Jung, E.M.; Stroszczynski, C.; Jung, F. Contrast Enhanced Ultrasonography (CEUS) to Detect Abdominal Microcirculatory
Disorders in Severe Cases of COVID-19 Infection: First Experience. Clin. Hemorheol. Microcirc. 2020, 74, 353–361. [CrossRef]
[PubMed]
39. Fox, S.E.; Akmatbekov, A.; Harbert, J.L.; Li, G.; Brown, J.Q.; Heide, R.S.V. Pulmonary and Cardiac Pathology in Covid-19: The
First Autopsy Series from New Orleans. medRxiv 2020. [CrossRef]
40. Ciceri, F.; Beretta, L.; Scandroglio, A.M.; Colombo, S.; Landoni, G.; Ruggeri, A.; Peccatori, J.; D’Angelo, A.; De Cobelli, F.;
Rovere-Querini, P.; et al. Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS):
An Atypical Acute Respiratory Distress Syndrome Working Hypothesis. Crit. Care Resusc. J. Australas. Acad. Crit. Care Med. 2020,
22, 95–97.
41. Carsana, L.; Sonzogni, A.; Nasr, A.; Rossi, R.S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo, R.; Antinori, S.; Corbellino, M.; et al.
Pulmonary Post-Mortem Findings in a Series of COVID-19 Cases from Northern Italy: A Two-Centre Descriptive Study. Lancet
Infect. Dis. 2020. [CrossRef]
42. Kirschenbaum, D.; Imbach, L.L.; Rushing, E.J.; Frauenknecht, K.B.M.; Gascho, D.; Ineichen, B.V.; Keller, E.; Kohler, S.; Lichtblau,
M.; Reimann, R.R.; et al. Intracerebral Endotheliitis and Microbleeds Are Neuropathological Features of COVID-19. Neuropathol.
Appl. Neurobiol. 2020. [CrossRef]
43. Keller, E.; Brandi, G.; Winklhofer, S.; Imbach, L.L.; Kirschenbaum, D.; Frontzek, K.; Steiger, P.; Dietler, S.; Haeberlin, M.; Willms, J.;
et al. Large and Small Cerebral Vessel Involvement in Severe COVID-19: Detailed Clinical Workup of a Case Series. Stroke 2020,
51, 3719–3722. [CrossRef] [PubMed]
44. Jensen, M.P.; Le Quesne, J.; Officer-Jones, L.; Teodòsio, A.; Thaventhiran, J.; Ficken, C.; Goddard, M.; Smith, C.; Menon, D.;
Allinson, K.S.J. Neuropathological Findings in Two Patients with Fatal COVID-19. Neuropathol. Appl. Neurobiol. 2020. [CrossRef]
45. Hernández-Fernández, F.; Sandoval Valencia, H.; Barbella-Aponte, R.A.; Collado-Jiménez, R.; Ayo-Martín, Ó.; Barrena, C.;
Molina-Nuevo, J.D.; García-García, J.; Lozano-Setién, E.; Alcahut-Rodriguez, C.; et al. Cerebrovascular Disease in Patients with
COVID-19: Neuroimaging, Histological and Clinical Description. Brain 2020, 143, 3089–3103. [CrossRef] [PubMed]
46. Helms, J.; Tacquard, C.; Severac, F.; Leonard-Lorant, I.; Ohana, M.; Delabranche, X.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Fagot
Gandet, F.; et al. High Risk of Thrombosis in Patients with Severe SARS-CoV-2 Infection: A Multicenter Prospective Cohort Study.
Intensive Care Med. 2020, 46, 1089–1098. [CrossRef]
47. Poissy, J.; Goutay, J.; Caplan, M.; Parmentier, E.; Duburcq, T.; Lassalle, F.; Jeanpierre, E.; Rauch, A.; Labreuche, J.; Susen, S.;
et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020, 142, 184–186.
[CrossRef]
J. Clin. Med. 2021, 10, 2646 13 of 13
48. Panigada, M.; Bottino, N.; Tagliabue, P.; Grasselli, G.; Novembrino, C.; Chantarangkul, V.; Pesenti, A.; Peyvandi, F.; Tripodi,
A. Hypercoagulability of COVID-19 Patients in Intensive Care Unit. A Report of Thromboelastography Findings and Other
Parameters of Hemostasis. J. Thromb. Haemost. JTH 2020. [CrossRef]
49. Rauch, A.; Labreuche, J.; Lassalle, F.; Goutay, J.; Caplan, M.; Charbonnier, L.; Rohn, A.; Jeanpierre, E.; Dupont, A.; Duhamel, A.;
et al. Coagulation Biomarkers Are Independent Predictors of Increased Oxygen Requirements in COVID-19. J. Thromb. Haemost.
2020. [CrossRef]
50. South, K.; Roberts, L.; Morris, L.V.; Mann, E.; Menon, M.; Knight, S.; Konkel, J.E.; Ustianowsk, A.; Bakerly, N.D.; Dark, P.M.; et al.
Severity-Stratified and Longitudinal Analysis of VWF/ADAMTS13 Imbalance, Altered Fibrin Crosslinking and Inhibition of
Fibrinolysis as Contributors to COVID-19 Coagulopathy. medRxiv 2020. [CrossRef]
51. Philippe, A.; Chocron, R.; Gendron, N.; Bory, O.; Beauvais, A.; Peron, N.; Khider, L.; Guerin, C.L.; Goudot, G.; Levasseur, F.; et al.
Circulating Von Willebrand Factor and High Molecular Weight Multimers as Markers of Endothelial Injury Predict COVID-19
in-Hospital Mortality. Angiogenesis 2021, 1–13. [CrossRef]
52. Huisman, A.; Beun, R.; Sikma, M.; Westerink, J.; Kusadasi, N. Involvement of ADAMTS13 and von Willebrand Factor in
Thromboembolic Events in Patients Infected with SARS-CoV-2. Int. J. Lab. Hematol. 2020, 42, e211–e212. [CrossRef]
53. Mancini, I.; Baronciani, L.; Artoni, A.; Colpani, P.; Biganzoli, M.; Cozzi, G.; Novembrino, C.; Boscolo Anzoletti, M.; De Zan,
V.; Pagliari, M.T.; et al. The ADAMTS13-von Willebrand Factor Axis in COVID-19 Patients. J. Thromb. Haemost. JTH 2021, 19,
513–521. [CrossRef] [PubMed]
54. Doevelaar, A.A.N.; Bachmann, M.; Hölzer, B.; Seibert, F.S.; Rohn, B.J.; Bauer, F.; Witzke, O.; Dittmer, U.; Bachmann, M.; Yilmaz, S.;
et al. Von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019. Crit. Care Med.
2021. [CrossRef]
55. Peyvandi, F.; Scully, M.; Kremer Hovinga, J.A.; Knöbl, P.; Cataland, S.; De Beuf, K.; Callewaert, F.; De Winter, H.; Zeldin, R.K.
Caplacizumab Reduces the Frequency of Major Thromboembolic Events, Exacerbations and Death in Patients with Acquired
Thrombotic Thrombocytopenic Purpura. J. Thromb. Haemost. JTH 2017, 15, 1448–1452. [CrossRef] [PubMed]
56. Scully, M.; Cataland, S.R.; Peyvandi, F.; Coppo, P.; Knöbl, P.; Kremer Hovinga, J.A.; Metjian, A.; de la Rubia, J.; Pavenski, K.;
Callewaert, F.; et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N. Engl. J. Med. 2019, 380,
335–346. [CrossRef] [PubMed]
57. Bhogal, P.; Jensen, M.; Collins, G.; Spooner, O.; Makalanda, L.; Hart, D.; Jaffer, O. Letter in Response to: Coagulation Markers
Are Independent Predictors of Increased Oxygen Requirements and Thrombosis in COVID-19. J. Thromb. Haemost. 2020, 18,
3382–3384. [CrossRef]
58. De Lizarrondo, S.M.; Gakuba, C.; Herbig, B.A.; Repessé, Y.; Ali, C.; Denis, C.V.; Lenting, P.J.; Touzé, E.; Diamond, S.L.; Vivien, D.;
et al. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. Circulation 2017, 136, 646–660. [CrossRef]
59. Derhaschnig, U.; Pachinger, C.; Jilma, B. Variable Inhibition of High-Shear-Induced Platelet Plug Formation by Eptifibatide and
Tirofiban under Conditions of Platelet Activation and High von Willebrand Release: A Randomized, Placebo-Controlled, Clinical
Trial. Am. Heart J. 2004, 147, E17. [CrossRef]
60. Van den Bergh, W.M.; MASH Study Group; Algra, A.; Dorhout Mees, S.M.; van Kooten, F.; Dirven, C.M.F.; van Gijn, J.; Vermeulen,
M.; Rinkel, G.J.E. Randomized Controlled Trial of Acetylsalicylic Acid in Aneurysmal Subarachnoid Hemorrhage: The MASH
Study. Stroke 2006, 37, 2326–2330. [CrossRef]
61. Nagahama, Y.; Allan, L.; Nakagawa, D.; Zanaty, M.; Starke, R.M.; Chalouhi, N.; Jabbour, P.; Brown, R.D.; Derdeyn, C.P.; Leira,
E.C.; et al. Dual Antiplatelet Therapy in Aneurysmal Subarachnoid Hemorrhage: Association with Reduced Risk of Clinical
Vasospasm and Delayed Cerebral Ischemia. J. Neurosurg. 2018, 129, 702–710. [CrossRef] [PubMed]
